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Abstract 
Chronic hypercapnic respiratory failure (CHF) represents a major issue in stable 
chronic obstructive pulmonary disease (COPD). Non-invasive Ventilation (NIV) 
improves pulmonary gas exchange function with decrease in PaCO2 and rise in pH. 
Long-term NIV reduces mortality in these patients and time to first exacerbations, but 
adherence to ventilatory therapy is poor. High Flow Oxygen Therapy (HFOT) could 
counterbalance the effect of intrinsic Positive End Expiratory Pressure (PEEPi) and 
optimize Ventilation/Perfusion ratio through the modification of breathing pattern; 
then, HFOT could be an appealing alternative to home NIV. Therefore, in order to 
assess HFOT effects on respiratory work of  breathing, compared to NIV as gold 
standard, we studied the consequences of these two form of non-invasive respiratory 
support on: inspiratory effort, as assessed by measuring transdiaphragmatic pressure; 
breathing pattern; gas exchange. Fourteen patients with hypercapnic stable COPD 
underwent  five 30-min trials, in a random order: HFOT at two flow rates (20 L/min 
and 30 L/min), both with open and closed mouth, and NIV. After each trial, standard 
oxygen therapy was reinstituted for ten min. Compared with baseline, HFOT and 
NIV significantly improved breathing pattern, although to different extents, and 
reduced inspiratory effort; however, arterial carbon dioxide oxygen tension decreased 
but not significantly. These results indicate a possible role for HFOT in the long-term 
management of patients with hypercapnic stable COPD, because of no rise in PaCO2, 
and improved respiratory mechanic. 
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Introduction 
 
1.1  Low-Flow Oxygen Therapy in Chronic Obstructive Pulmonary Disease 
(COPD) – State of the Art  
 
- Respiratory Failure in COPD Patients 
Respiratory failure is a condition in which the respiratory system fails in one or both 
of its gas exchange functions, i.e. oxygenation of and / or elimination of carbon 
dioxide from mixed venous blood. It is conventionally defined by an arterial oxygen 
tension (PaO2) of < 8.0 kPa (60 mmHg), an arterial carbon dioxide tension (PaCO2) 
of  > 6.0 kPa (45 mmHg) or both. Failure of the lung, i.e. the gas-exchanger organ, 
and of the pump (i.e., chest wall, respiratory muscles and respiratory central nervous 
controllers)  that ventilates the lung, may coexist in Chronic Obstructive Pulmonary 
Disease (COPD). COPD is marked by an airflow limitation with persistent and 
progressive courses of breathlessness, frequently associated with chronic productive 
cough and chest tightness [1, 2]; according to the WHO, COPD is the fourth leading 
cause of  death and is supposed to become the third leading cause by 2020 [3]. 
Ventilation / Perfusion mismatch and decreased capillary surface area due to 
emphysema account for COPD - related hypoxemia, while airflow obstruction 
leading to hypoventilation and respiratory muscles impairment account for COPD – 
related hypercapnia. More importantly, the dynamic hyperinflation that develops in 
these patients, due to limitation of expiratory flow, imposes a severe strain on the 
respiratory muscles because of the additional load that is placed on them (intrinsic 
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positive end-expiratory pressure (PEEPi). Carbon dioxide levels and ventilatory 
capacities are the best indicators of a poor prognosis in COPD patients [4, 5] 
- Acute Respiratory failure and COPD  
 According British Thoracic Society Guidelines for oxygen use in adults in healthcare 
and emergency settings [6], oxygen therapy is aimed to achieve, in acutely ill 
patients, a normal or near-normal saturation, being  the recommended target of SpO2 
94-98%; in patients at risk for hypercapnic respiratory failure (i.e., Chronic 
Obstructive Pulmonary Disease – COPD), target SpO2 ranges between 89-92%. 
Latters have an increased hazard to get worse carbon dioxide arterial content and pH, 
because of reduced respiratory drive as oxygen arterial content rises. Furthermore, as 
reported by ERS/ATS guidelines [7], for patients with Acute Respiratory Failure 
(ARF) leading to acute or acute-on-chronic respiratory acidosis (pH ≤ 7.35 + PaCO2 
> 45 mmHg) due to COPD exacerbation, bilevel Non Invasive Ventilation (NIV) is 
strongly recommended: indeed, the task force recommends a trial of bilevel NIV in 
patients considered to require endotracheal intubation and mechanical ventilation, 
unless the patient is immediately deteriorating. Actually, the common devices for 
initial oxygen therapy are: nasal cannulae (oxygen delivery up to 6 L/min) or simple 
face mask (oxygen delivery between  5–10 L/min); Venturi mask (low-flow masks 
that use the Bernoulli principle to entrain room air when pure oxygen is delivered 
through a small orifice, resulting in a large total flow at predictable FiO2, up to 60%); 
reservoir mask (oxygen delivery up to 15 L/min – FiO2 ~ 80%). The FiO2 exactly 
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provided to the patients is however unpredictable, because of the entrainment of room 
air depending on individual breathing pattern and peak inspiratory flow rate.  Indeed, 
during acute phase of illness, patient’s inspiratory flow rate frequently exceeds the 
flow capabilities of the afore mentioned low-flow oxygen delivery devices. 
Conventional Oxygen Therapy (COT), carrying cool and anhydrous gas, induces 
nasal and oral discomfort, interfering with patient’s compliance to treatment: if 
inspired humidity deviates from an optimal level, a progressive dysfunction of upper 
airway mucosa begins. Furthermore, inspired humidity and temperature influences 
physiologically lung mechanics, by directly affecting airway patency (airway 
resistances increase as lower temperature) and lung compliance (damage of surfactant 
at low, non-isothermal temperature, with reabsorption atelectasis)  [8].  
- Chronic Respiratory Failure and COPD  
Chronic respiratory failure is associated with adverse health outcomes in COPD: 
impaired exercise tolerance [9], pulmonary hypertension [10], skeletal muscle 
dysfunction [11], polycythemia, impaired health related quality of life, increased risk 
of hospitalization [12] and earlier death [13]. As reported recently in a longitudinal 
analysis of data from the Swedish National register of COPD, performed by Sundh 
and Elkstrom, the prevalence and incidence of hypoxemic respiratory failure in 
COPD patients is low (2.4%) and is well predicted by more severe air flow limitation 
and worse health status, being the risk higher in patients with GOLD stages IV and 
GOLD groups C or D [14]. The degree of hypoxemia is directly related to mortality 
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in COPD, and correcting hypoxemia with LTOT increases survival [15]. As reported 
by Ergan and Nava [16], persistent hypoxemia induces pulmonary vasoconstriction 
and remodeling of pulmonary circle, resulting in right hearth failure; the secondary 
erythrocytosis causes increased serum viscosity. These consequences increase 
mortality in COPD patients. Oxygen therapy may reverse pulmonary vasoconstriction 
and stabilize or reduce pulmonary artery pressure [17]. Improvement of pulmonary 
hemodynamics is enhanced if oxygen is used continuously, and this effect seems to 
be sustainable over the years [18]. A trial conducted in 1980 [19], showed that 
continuous long term treatment with supplemental oxygen reduced mortality among 
COPD patients and severe resting hypoxemia (PaO2 < 55 mmHg), compared to 
nocturnal oxygen therapy alone; this trend was particularly striking for patients with 
carbon dioxide retention. In the same years, another controlled trial of long term 
oxygen therapy (LTOT) in COPD patients, showed that in long term survivors (5 
years of follow-up) arterial oxygenation did seem to stop worsening of respiratory 
failure [20]. In 1990s, two trials evaluated long term treatment with supplemental 
oxygen in COPD patients who had a mild to moderate daytime hypoxemia; neither 
trial showed a mortality benefit [21, 22]. More recently, a randomized trial of long 
term oxygen therapy for stable COPD patients with resting or exercise-induced 
moderate desaturation (Long Term Oxygen Treatment Trial – LOTT) failed to 
demonstrate that the use of long term supplemental oxygen had effect on the time 
until the first hospitalization or death [23]. On the other hand, Ekstrom and 
coworkers, in a systematic review, have reported that LTOT in COPD patient who 
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would not otherwise qualify for home oxygen therapy, decreases breathlessness – a 
cardinal symptom of the disease – during exercise tests [24]. Instead, Literature data 
describe more evidences in favor of long term NIV in stable hypercapnic COPD. 
Patients with chronic respiratory failure and hypercapnia have severe dyspnea, lower 
quality of life and even increased mortality. NIV could improve gas exchange 
function by increasing tidal volume and ameliorating Ventilation / Perfusion ratio; by 
improving respiratory centers’ sensitivity to CO2; by relaxing respiratory muscle 
fatigue [25, 26]. In a recent meta-analysis of randomized controlled trials, Liao et al. 
have reported that long term NIV in stable hypercapnic COPD patients decreases 
PaCO2, compared to LTOT alone; in particular, patients in the NIV group mainly 
aimed at reducing PaCO2 had a lower risk of mortality than those in the control group 
[27]. In a randomized clinical trial of COPD patients with persistent hypercapnia 
[28], Murphy at al. randomized 59 patients to home oxygen alone and 57 patients to 
home oxygen plus home NIV, 64 patients completing 12 months of study-period. The 
median time of hospital readmission or death was significantly lower in NIV group 
compared to the home oxygen alone group. Poor adherence to long term NIV 
(discomfort, inability to fit interface, poor tolerance) represents actually a major issue 
in this patients’ population. 
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1.2  High Flow Oxygen Therapy  
– Mechanism of Action and Rationale of Application 
 High Flow Nasal Cannula Oxygen Therapy (HFOT) is a non-invasive respiratory 
support consisting of an air-oxygen blender with adjustable FiO2 (21-100%), that 
delivers a modifiable gas flow (2L/min up to 60 L/min) to a heated chamber where 
the gas is heated and humidified. The gas mixture is then routed through a highly 
performance circuit, containing water (44 mg H2O/L) to be delivered at 37°C  (range: 
37-34-31°C) to the patient via short, wide bore binasal prongs [29]. Potential 
mechanisms of action and clinical accomplishment are here described [30]: 
 
 
HFOT use has been widely reported either in pediatric or adult patients for treatment 
of AHRF, while the effects in hypercapnic patients have been less investigated. First 
Tobin and Groves [31] observed that studies on pediatric patients using HFOT 
reported similar efficacy compared to nasal continuous positive airway pressure 
(CPAP); so in a study on healthy adult volunteers they applied high flow nasal 
Adapted from Spoletini et al. - Chest, July 2015 
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interface and recorded pharyngeal pressure with flow from 0 to 60 L/min. They found 
that high flow nasal therapy was associated with the generation of significant positive 
pharyngeal airway pressure in volunteers (~ 4-5cmH2O), which is flow dependent 
and also dependent on whether the person is breathing with mouth open or closed. 
Nevertheless, as reported in Literature  [32, 33], pressure and air flow dynamics 
markedly differ between HFOT and CPAP. During CPAP, pressure is generated 
within the device and is dependent on the flow in the inspiratory line; the device 
supplies a constant and steady pressure at mouth and nares and resistance is provided 
by the expiratory valve. During HFOT, pressure is developed within the nasal cavity 
and results from the flow through the cannula in combination with patient’s 
breathing; the resistance is determined by patient’s breathing out against the high 
velocity of continuous incoming gas flow, the leak between the   nares and cannula  
and by alae nasae muscle activation that stiffens the airway. Without HFOT, the 
inspiratory pressure in the nasal cavity becomes negative with onset of inspiration, 
but when HFOT is present, the pressure remains above atmosphere for most of 
inspiratory phase. This increase would raise the driving pressure for inspiration (∆P 
N-T = pressure gradient between the Nose and the Trachea) and the low level of 
positive airway pressure could reduce the Work Of Breathing (WOB) by providing a 
small amount of inspiratory assistance. In particular, Park et al [34] observed that for 
each increase of 10 L/min in flow rate, mean airway pressure increases by 0,69 
cmH2O (mouth closed) or 0,35 cmH2O (mouth open). So, HFOT increases expiratory 
but decreases inspiratory resistance of the upper airway (nasal resistance in adults 
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contributes up to half of total airway resistance) while CPAP does not alter 
resistances throughout the respiratory cycle compared to normal breathing.         
HFOT differs from NIV: in the first case, airway pressure is variable, and depends on 
flow  (higher the flow, higher the pressure), on type of breathing (lower pressure in 
mouth breathers) and on phase of respiratory cycle (inspiration-expiration); more, no 
trigger system occurs. During NIV, a constant level of pressure(s) or volume(s) is 
applied to the airways, and patient and ventilator interact through a trigger system. 
NIV reduces respiratory WOB in direct proportion to level of inspiratory pressure 
assist and application of Positive End Expiratory Pressure (PEEPe) counterbalancing 
intrinsic PEEP (PEEPi); such a number of Literature data have reported a reduction 
of relative risk in mortality, re-intubation and treatment failure for patients affected 
by respiratory failure due to COPD exacerbation and acute cardiogenic pulmonary 
edema.  Actually, one of major indication for NIV use is the treatment of hypercapnic 
respiratory failure due to COPD exacerbation, because NIV improves pulmonary gas 
exchange function either unloading respiratory muscle or through optimization 
Ventilation / Perfusion Ratio (Va/Q) with arterial PaCO2 reduction and rise in pH. 
HFOT seems to interfere with CO2 production and CO2 elimination and there are 
different possible explanations for this. HFNC generates a small amount of positive 
airway pressure (~ 5 cmH2O) that could counterbalance PEEPi in COPD patients, 
reducing the resistive load imposed at the beginning of inspiration and allowing CO2 
clearance. Furthermore, HFOT seems to reduce metabolic cost of breathing: the 
provision of adequately warmed and humidified gas through the nasal pharynx 
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reduces the metabolic work associated with gas conditioning and improves 
conductance and pulmonary compliance compared to dry, cooler gas [35]. 
Furthermore, flushing the dead space of the nasopharyngeal cavity results in refresh 
of overall dead space (upper airway becomes a reservoir of humid, warmed gases 
readily available at each inspiration) and in alveolar ventilation as a greater fraction 
of minute ventilation. Thus, there is an improvement in the efficiency of respiratory 
efforts. The essential clinical criteria to remain on non-invasive respiratory support 
modes are effective spontaneous respiratory effort and CO2 elimination. Hypercapnia 
is the most common reasons for progressing to more invasive forms of ventilatory 
support. Therefore, if CO2 retention can be reduced or eliminated, many patients can 
be spared noninvasive or invasive mechanical ventilation and the associated potential 
lung injury [36, 37]. During HFOT a reduction of respiratory rate and minute 
ventilation have been reported, with no changes in paCO2, probably because of the 
increase of tidal volume and/or decrease of dead space volume [38]. 
1.3  High Flow Oxygen Therapy and Hypercapnic Respiratory Failure in COPD 
Patients  
– Data from Literature 
In 2016, Fraser and coworkers performed a randomized cross-over study aimed to 
assess short-term physiological responses to HFNC therapy in 30 COPD males 
chronically treated with LTOT(> 15 hours/day) [39]. LTOT (2-4 L/min) through 
nasal cannula was compared with HFOT at 30 L/min plus supplemental oxygen. 
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They found that transcutaneous carbon dioxide, transcutaneous oxygen, Inspiratory / 
Expiratory Ratio and respiratory rate were significantly lower in HFOT ; tidal volume 
and end-expiratory lung volume, measured via electrical impedance tomography, 
were significantly higher in HFOT group. In the same year, Fricke et al. measured, in 
a tracheostomized COPD patient, carbon dioxide and airway pressure via sealed ports 
in the tracheostomy cap and monitored transcutaneous CO2 and tidal volumes [40]. 
HFOT (30 L/min mixed with 3 L/min oxygen) was administered repeatedly at 15-
minutes intervals; inspired CO2 decreased instantly with onset of HFOT, followed by 
a reduction in transcutaneous/arterial CO2. Minute ventilation on nasal high flow was 
also reduced by 700 ml, indicating that nasal high flow led to a reduction of dead 
space ventilation thereby improving alveolar ventilation. Since the reduction in 
hypercapnia was similar to that reported with effective NIV treatment, the Authors 
conclude that  HFOT may become an alternative to NIV in hypercapnic respiratory 
failure. Braunlich and coworkers, in order to describe the possible longtime 
effectiveness of HFNC in hypercapnic respiratory failure, enrolled eleven COPD 
patients with stable hypercapnia [41]. Patients were adjusted to HFOT system with a 
flow of 20 L/min and after six weeks were switched to NIV for another six weeks 
period. Results were that six weeks of HFNC led to significant decreases in resting 
paCO2. After decreasing by HFOT therapy, NIV was able to preserve normocapnia; 
no differences in PaCO2 were observed between the two methods of noninvasive 
ventilatory support. More recently Vogelsinger et al. performed a study in order to 
compare the efficacy and safety of HFOT with those of COT in normo- and 
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hypercapnic stable COPD patients [42]. Despite the brief period of observation (COT 
and HFOT for 60 min each, separated by a 30 min washout phase), the Authors 
observed a significant decrease in PaCO2 and increased PaO2; lower oxygen levels 
were effective in correcting hypoxemic respiratory failure and reducing hypercapnia, 
leading to a reduced amount of oxygen consumption. These findings open the way to 
further studies, in order to assess the feasibility of home HFOT for chronic  
hypercapnic respiratory failure in stable COPD patients requiring noninvasive 
mechanical ventilation. 
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Aim of the Study 
Compare the physiological effects of standard oxygen therapy, NIV and HFOT 
oxygen therapy in patients with stable hypercapnic COPD, as assessed at two flow 
rates with open and closed mouth. In addition to breathing pattern and arterial blood 
gases (ABGs), we measured the inspiratory effort by measuring the trans-
diaphragmatic pressure (Pdi). 
 
Patients 
Fourteen consecutive COPD patients with stable chronic hypercapnic respiratory 
failure (CHRF), referring to our outpatient clinic for periodical controls, were 
enrolled in the study. Patients’ characteristics are shown in table R1. The study was 
approved by the Sant’Orsola Malpighi Hospital. Written informed consent was 
obtained before enrolment. The study is registered with ClinicalTrials.gov, number 
NCT02363920. Clinical stability was defined as lack of 1) exacerbations in the 
previous three months, and 2) changes in the medications, as assessed from electronic 
records. Enrolment criteria were pH > 7.35 < 7.45 and PaCO2 > 45 mmHg with  
PaO2/FiO2 > 200. Patients with cancer, neuromuscular disease or chronic heart failure 
were excluded.  
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Protocol 
The patients were studied in a semi-recumbent position. They were asked to breathe 
for a few minutes through a standard nasal cannula (baseline). Data were recorded 
during five 30-minute trials applied according to a predetermined computer-generated 
random sequence,. After each trial standard oxygen therapy through a nasal cannula 
was reinstituted for 10 min (baseline). In all of the trials the oxygen was administered 
to maintain SpO2 between 91% and 94%, keeping the FiO2 constant for the NIV and 
HFOT trials. 
 
Noninvasive ventilation 
Noninvasive ventilation (NIV) was administered using ventilators equipped with a 
dedicated NIV software (Vivo 50 Breas, Molnlycke, Sweden) or V60 (Respironics 
V60 ventilator, Philips), through a full-face mask (PerforMax Face Mask,- Philips 
Respironics). Great care was taken to avoid any possible air leaks. Correct 
positioning of the mask was reassessed at the beginning of each trial. The expiratory 
pressure (EPAP) was set by default to 4 cmH20 (the minimum allowed by the 
ventilators), while the peak inspiratory pressure (IPAP) was set according to the 
patient’s tolerance and to avoid tidal volumes (VTs) >7 ml/Kg/Predicted Body 
Weight. 
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High Flow Oxygen Therapy  
HFOT was delivered at two flow rates, 20 and 30 L/min. At each flow rates we 
performed two separate trials, asking the patients to breathe with their mouth open or  
closed. For this purpose, the patient was requested and instructed to breathe through 
both the nose and mouth in one trial and with the nose only in the other one trial. The 
presence or absence of flow at the mouth was assessed using a pneumotachograph 
connected to a mouthpiece. The two flow rates used for the investigation had been 
previously defined by assessing patient comfort during HFOT, ion a flow range 
between 10 and 50 L/min, through using a visual analog scale, in eight different 
COPD patients with CHRF. It is worth mentioning, that six patients scored the 
highest comfort at 30 L/min, which was then selected as the highest value flow rate 
for the study. NHFOT was delivered by using an AIRVO through an Optiflow nasal 
interface (Fisher & Paykel Healthcare, Auckland, New Zealand). With this system, 
the gas mixture is routed through a circuit to be delivered to the patient via short, 
large bore nasal prongs at 37°C with 100% relative humidity. 
Measurements 
Esophageal (Pes)  and gastric (Pga) pressures were measured using separate balloon-
tipped catheters (Microtek, Medical B.V., Zutphen, Netherlands) positioned in the 
mid-esophagus and in the stomach respectively and connected to two differential 
pressure transducers (Micro Switch, Honeywell, USA). Esophageal and gastric 
balloons were filled with 0.5 and 1 ml of air, respectively [43]. Correct positioning of 
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the catheters was evaluated as previously described [44]. Transdiaphragmatic (Pdi) 
pressure was obtained by subtracting Pes from Pga. The inspiratory efforts generated 
by the diaphragm was assessed by the inspiratory swing in Pdi , i.e., baseline to peak. 
The Pdi-time product of the was calculated as the integral of inspiratory Pdi over one 
minute, as already described [45].  Flow was measured using a pneumotachograph 
(Hans Rudolph, Model 3700; Shawnee, KS, USA) connected to a mouthpiece during 
the baseline and HFOT trials with a closed mouth, while and at the airways opening, 
between the mask, and  the Y-piece during trials with an open mouth. Tidal volume 
was obtained by the integration of the flow, in the NHF trials with the mouth open. 
Flow and VT were obviously not determined in the two HFOT sessions with open 
mouth. The patient’s own inspiratory time (TI,p)  and expiratory time (TE,p) time 
were obtained from the Pdi tracing. TI,p was determined as the time lag between the 
onset of the positive Pdi swing above baseline (i.e., start of inspiratory effort) and the 
point where Pdi started to fall toward baseline,. while TE,p was determined as the 
time distance between this latter point and the onset of the following inspiration [46]. 
The Ppatient’s respiratory rate (RRp) was also determined from the Pdi tracing [46]. 
PEEPi (PEEPi,dyn) was obtained from the Pdi signal, as the value of Pes at the point 
of zero flow, only in the trials where flow was measured [47]. Patient comfort was 
assessed during each trial using a visual analogue scale from 0 to 10, where the 
former is the worst comfort and the latter the best. best. At the end of each run, just 
before ABG assessment, the patient was asked to score her/his comfort on the scale 
[48]. 
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Statistical Analysis 
The results are expressed as mean ± standard deviation (SD). Differences between the 
different trials were determined using the Friedman test. and The difference between 
the two HFOT trials with the mouth open and closed interfaces was assessed using 
the Wilcoxon signed-rank test. P values < 0.05 were considered statistically 
significant. Comparison between groups, were adjusted for multiplicity in post-hoc 
analysis using the Bonferroni’s test. All of the analyses were performed using 
statistical package Stata Intercooled for Windows, version 12.0  (STATA, College 
Station, TX). 
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Table 1. Baseline Characteristics of the Patients 
 n=14 
Age, yrs 73.5± 5.2 
Sex (M/F) 9/6 
Body Mass Index 
(BMI) 
26.65±4.8 
FEV1 (% pred) 44.29  ± 13.59 
LTOT duration 
(months) 
37.3±12 
Previous “acute” NIV  
(n/total) 
5/14 
Actual Smokers 
(n/total) 
6/14 
Charlson Index 2-11 
Secretions 2 ± 1.1 (0-3) 
Ex- Smokers (n/total) 
 
8/14 
 
 
 
 
 
 
Data are presented as mean ± SD, minimum and maximum value. NIV=Non 
Invasive Ventilation, FEV1= Forced Expiratory Volue in the 1st second, 
LTOT=Long Term Oxygen Therapy 
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Table 2. Breathing Pattern, Inspiratory Efforts and Lung Mechanics 
in different setting 
 
Legend 
*p= 0.006 HFOT 20 closed vs baseline; p= 0.01 HFOT 20 open vs baseline; p= 0.007 
HFOT 30 closed vs baseline; p= 0.02 HFOT 30 open vs baseline; p= 0.002 NIV vs 
baseline. 
†p= 0.022 HFOT 20 closed vs baseline; p= 0.007 HFOT 30 closed vs baseline; p= 
0.002 NIV vs baseline. 
‡p= 0.015 HFOT 20 closed vs baseline; p= 0.007 NIV vs baseline. 
ξp= 0.005 HFOT 20 closed vs baseline; p=0.005 HFOT 30 closed vs baseline; p=0.03 
HFOT 30 open vs baseline; p=0.001 NIV vs baseline. 
¶p<0.003 NIV vs HFOT 20 closed; p=0.003 NIV vs HFOT 20 open; p=0.007 NIV vs 
HFOT 30 closed; p=0.005 NIV vs HFOT 30 open. 
**p=0.005 HFOT 20 closed vs baseline; p=0.002 HFOT 20 open vs baseline; 
p=0.004 HFOT 30 closed vs baseline; p=0.015 HFOT 30 open vs baseline; p=0.001 
NIV vs baseline. 
 Baseline HFOT 20 
(Closed) 
HFOT 20 
(Open) 
HFOT 30 
(Closed) 
HFOT 30 
(Open) 
NIV 
TI,p 
(seconds) 
 
0.95±0.2 0.85±0.4 0.96±0.2 0.94±0.3 0.92±0.3 1.00±0.2 
TE,p 
(seconds) 
 
1.94±0.4 2.35±0.4* 2.19±0.5*
 
2.30±0.5* 2.20±0.3* 2.61±1.0* 
Breathing 
Frequency 
(Breaths/min) 
 
24.8±2.3 19.01±5.2†
 
20.08±5.8 18.7±3.6† 19.64±2.8 17.8±3.8† 
Tidal Volume 
(mL) 
 
314.50±84 391.22±106‡  364.22±66  456.2±100‡ 
Pdi Swing 
(CmH2O) 
 
13.5±6.7 8.7±4.1ξ 12±5.8 8.2±3.4ξ 10.2±5.2ξ 5.1±2.2ξ¶ 
PTPdi/min 
(cmH2O x 
sec/min) 
 
238.3±82.1 164.2±51.3** 172.7±45.4**
 
143.2±48.9** 157.3±56.9** 101.7±42.9**†† 
PEEPi,dyn 
(cmH2O) 
 
2.12±0.9 1.48±0.7‡‡
 
 1.03±0.6‡‡  0.9±0.02‡‡ 
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††p<0.004 NIV vs HFOT 20 closed; p=0.006 NIV vs HFOT 20 open; p=0.016 NIV 
vs HFOT 30 closed; p=0.02 NIV vs HFOT 30 open. 
‡‡p=0.01 HFOT 20 closed vs baseline; p=0.003 HFOT 30 closed vs baseline; 
p=0.001 NIV vs baseline. 
Data are presented as mean±SD. HFOT, high flow oxygen therapy; NIV, noninvasive ventilation; 
Pdi, trans-diaphragmatic pressure; PEEPi,dyn, intrinsic dynamic positive end expiratory pressure; 
PTPdi, pressure–time product of the trans-diaphragmatic pressure; TE,p, patient’s expiratory time; 
TI,p, patient’s inspiratory time. 
 
Table 3. Arterial blood gas values and comfort scores at different settings 
  
 Baseline HFOT 20 
(closed) 
HFOT 30 
(closed) 
NIV 
pH 
 
7.40±0.03 7.42±0.04 7.43±0.04 7.44±0.04 
PaCO2 
 
61.2±9.2 57.2±11.7 55.7±10.6 55.2±11.9 
PaO2 
 
70.6±12.6 70.3±17.3 61.5±11.1 83.3±33.2 
Comfort 
Score 
7 (5–8) 5.5 (5–8) 5.5 (2–8) 5 (3–5) 
 
Data are presented as mean ± SD unless indicated otherwise. Comfort score was 
assessed with a scale where 0 is the worst comfort and 10 the best. The data are 
presented as the median (interquartile 25–75). 
HFOT, high flow oxygen therapy; NIV, non-invasive ventilation. 
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Results 
As shown in table 2, compared with baseline, breathing frequency was significantly 
reduced in HFOT trials with the mouth closed and with NIV. Patient’s own 
expiratory time (TE,p) was significantly prolonged and VT higher compared with 
baseline for all the settings. The patient’s own inspiratory time (TI,p) was no different 
between trials. Pdi swing and diaphragm pressure time product (PTPdi) were reduced 
compared with baseline in all trials. However, the reductions observed during NIV 
were significantly larger, as opposed to all of the HFOT trials. Dynamic intrinsic 
positive end expiratory pressure (PEEPi, dyn) was significantly reduced compared 
with baseline in all trials. Breathing frequency, TI.p and TE.p, did not change 
between the different HFOT trials with the mouth closed or open, while Pdi at HFOT 
20 L/min, was statistically higher with the mouth closed compared with open. As 
shown in table 2, the PaCO2 level decreased but not significantly with HFOT at 30 
L/min and NIV compared with standard oxygen. Also shown in table 3, comfort did 
not vary among the different trials. 
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Discussion 
 
The main findings in our study are threefold. First, compared with low flow oxygen, 
HFOT and NIV both reduce the respiratory muscle load, as well documented by Pdi 
swing and Diaphragm Pressure Time Product (PTPdi) reduction. Second, breathing 
frequency was significantly reduced during HFOT with mouth closed and with NIV, 
compared with baseline. Third, there was a trend toward PaCO2 reduction during 
HFOT 30 L/min trial and NIV, juxtaposed to low flow oxygen, also if, in this last 
case, statistical significance wasn’t  reached. Respiratory failure is still an important 
complication of chronic obstructive pulmonary disease (COPD) and hospitalization 
with an acute episode being a poor prognostic marker. Changes in lung mechanics are 
thought to be the major determinants of the physiological abnormalities that 
characterize hypercapnic respiratory failure. In practice, a subject would need to 
increase their ventilation very substantially to overcome the wasted ventilation in 
high ventilation/perfusion ratio units, but their inability to do so despite the 
respiratory stimulus that a rising PaCO2 tension provides has been the subject of 
much debate. At last, as well described by Moxham [55], respiratory muscle pump 
plays a central role in the development of hypercapnia, being affected to some extent 
by the load that it has to overcome, i.e. the expiratory airflow limitation seen in 
severe COPD, but also by its own capacity to generate pressure, which is 
significantly reduced by the respiratory muscle shortening that accompanies 
pulmonary hyperinflation. Furthermore, chronic respiratory failure is associated with 
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adverse health outcomes in COPD: impaired exercise tolerance [9], pulmonary 
hypertension [10], skeletal muscle dysfunction [11], polycythemia, impaired health 
related quality of life, increased risk of hospitalization [12] and earlier death 
[13].Two trials that were conducted in the 1970s showed that long term treatment 
with supplemental oxygen reduced mortality among patients with COPD and severe 
resting hypoxemia [19,20]. More recently, the Long Term Oxygen Treatment Trial 
(LOTT), designed to test whether long term treatment with supplemental oxygen 
would result in a longer time to death or hospital admission than no use in stable 
COPD patients with resting or exercise induced desaturation, has failed to prove it.  
As reported by a recent Cochrane review [24], the efficacy of oxygen therapy for 
breathlessness and health-related QoL was assessed in COPD patients who did not 
meet the criteria for LTOT; the authors concluded that oxygen can relieve 
breathlessness when given during exercise to mildly hypoxemic and non-hypoxemic 
people with COPD who would not otherwise qualify for home oxygen therapy. 
However, actually  there are more evidences in favor of the use of home noninvasive 
ventilation + oxygen compared to oxygen alone in stable hypercapnic COPD patients 
[27, 28]. It seems that home noninvasive ventilation unloads respiratory muscles and 
improves ventilatory response to hypercapnia, which could be expected to act as a 
relevant effect of treatment, allowing a more robust and adaptive response to the 
adverse physiological challenge of an acute PaCO2 increase during an exacerbation. 
Furthermore, long term NIV in COPD patients may contribute to airway remodeling 
and improved ventilation / perfusion matching [56]. However, intolerance and major 
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side effects (incorrect use of interface, gas – humidification, ventilator settings) led to 
poor adherence to ventilatory therapy in stable COPD patients. HFOT could represent 
an innovative, efficient third option in this population. Physiologically, pressure loads 
and ventilation loads imposed to respiratory system are balanced with capabilities – 
that is, neural drive and muscles’ strength and endurance. HFOT acts on both the 
arms of this balance. The design of the nasopharynx facilitates humidification and 
warming of inspired gas by contact with the large surface area. By definition, this 
large wet surface area and nasopharyngeal gas volume can account for an appreciable 
resistance to gas flow. In addition, after analyzing nasal and oral flow-volume loops, 
Shepard and Burger showed that the nasopharynx has a distensibility that contributes 
to variable resistance [50]. When inspiratory gas is drawn across this large surface 
area, retraction of the nasopharyngeal boundaries results in a significant increase in 
inspiratory resistance compared to expiratory resistance. CPAP has been shown to 
reduce this supraglottic resistance up to 60% by mechanically splinting the airways 
[51]. HFOT most likely minimizes the inspiratory resistance associated with the 
nasopharynx by providing nasopharyngeal gas flows that match or exceed a patient’s 
peak inspiratory flow. This change in resistance translates to a decrease in resistive 
work of breathing, and so in  reduction of pressure loads. Furthermore, HFOT 
indirectly influences respiratory muscles’ metabolism: we found a reduction of 
respiratory rate compared to low flow oxygen therapy; these results are analogous to 
those of other studies [35,40,52]. The reduction of respiratory rate reduces CO2 
production and O2 uptake in respiratory muscles. HFOT ameliorates Va/Q, exhibiting 
25 
 
various remarkable changes in breathing efforts in COPD patients: a decrease in 
respiratory rate and an increase in tidal volume result in a reduced minute ventilation, 
without rising in PaCO2, suggesting an improvement of alveolar ventilation.  The 
most likely explanation for this response seems to be related to the increase in the 
expiratory resistance, with a mechanism different from that of CPAP. During CPAP, 
pressure is generated within the device and is dependent on the flow in the inspiratory 
line; the device supplies a constant and steady pressure at mouth and nares and 
resistance is provided by the expiratory valve. During HFOT, expiratory resistance 
are provided by patient’s effort against continuous incoming, at high velocity ,of 
fresh gases in nasal cavity, and by the leak between cannula and nares. The 
respiratory pattern elicited by HFOT resembles pursed lip breathing which is, 
however, associated with increased work of breathing and patients cannot maintain 
this pattern over a longer time period [25]. In contrast, during HFOT we could 
demonstrate for the first time that inspiratory effort was reduced. Several mechanisms 
have been advocated to explain the effect of HFOT on work of breathing, such as 
minimization of inspiratory resistance, attenuation of the activation of cold receptors 
or osmoreceptors in the nasal mucosa inducing bronchoconstriction, and reducing the 
anatomical dead space in the upper airways. Data from published clinical studies 
support the theory that HFT eliminates dead space because of the immediate impact 
on ventilation rates. A study by Dewan and Bell investigated exercise tolerance in 
COPD patients receiving respiratory support by transtracheal catheters (TTC), and 
compared low and high flows through nasal cannulae to low and high flow through 
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the TTCs [54]. TTCs are catheters placed in the patient’s trachea for the direct 
purpose of increasing respiratory efficiency by tracheal gas insufflation dead space 
washout. Dewan and Bell showed that exercise tolerance was greater for high flow 
than low flow regardless of method of administration (p < 0.01), but high flow via 
nasal cannula was just as effective for dead space washout as with TTC. These data 
confirm that dead space washout is a primary mechanism of action during HFOT. 
Furthermore, it’s well known that providing distending pressure to the lungs results in 
improved ventilatory mechanics by optimizing lung compliance and assists with gas 
exchange by maintaining patency of alveoli. Whereas HFOT is not necessarily 
intended to provide CPAP, if gas flow and nasal prong dimensions are set 
appropriately for patient size, distending pressure can be accomplished, quantifiable 
in  a modest degree of positive pressure, unlikely to be above 5–6 cmH2O; this small 
amount of positive pressure  may also partially counteract the threshold load imposed 
by the presence of PEEPi. The reduction in transcutaneous CO2 in Fraser’s study and 
in PaCO2, despite not being statistically significant, in our investigation, support the 
hypothesis that it is possible to reduce hypercapnia using HFOT. Indeed, carbon 
dioxide directly controls the activity of inspiratory muscles alone and therefore its 
reduction may lead to a decrease in diaphragmatic effort. We cannot rule out the 
effect of a higher PaO2/FiO2 ratio as explanation for the PaCO2 increase during 
baseline conditions. Moreover baseline conditions consisted of breathing oxygen 
through nasal cannula, and under these conditions, FiO2 cannot be controlled 
depending on the breathing pattern, the patient’s inspiratory flow and whether 
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patients breathe predominantly through the mouth or the nose. Therefore, the 
decrease in PaO2 during HFOT can be explained by a higher actual FiO2 under nasal 
oxygen therapy compared with HFOT. We have further explored the physiological 
changes induced by mouth or nasal breathing, since it is totally unrealistic to assume 
that patients recruited for long-term treatment will always breathe with their mouth 
perfectly ‘sealed’. It has been shown that breathing with the mouth open negatively 
influences the generation of a positive pressure. Despite this, we were unable to 
demonstrate any ‘detrimental’ effect of this behavior on the breathing pattern and 
inspiratory effort compared with breathing with the mouth closed. Similar results 
have been recentely obtained by  Vogelsinger et al. [42]. The Authors performed a 
study in order to compare the efficacy and safety of HFOT with those of conventional 
oxygen therapy (COT) in normo- and hypercapnic stable COPD patients. Despite the 
brief period of observation (COT and HFOT for 60 min each, separated by a 30 min 
washout phase), a significant decrease in PaCO2 and increased PaO2 was assessed; 
lower oxygen levels were effective in correcting hypoxemic respiratory failure and 
reducing hypercapnia, leading to a reduced amount of oxygen consumption.  The 
results of this study show overall similar acute physiological changes between HFOT 
and NIV, and support the need for further investigations to assess the effectiveness of 
domiciliary HFOT versus NIV in patients with stable hypercapnia. Obviously our 
findings could not be translated to the situation of an acute exacerbation of COPD. In 
conclusion, HFOT is an appealing technique as a potential alternative to NIV in 
stable hypercapnic COPD because is less of a burden, and because HFOT provides a 
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more physiological humidification and heating of the airways, a more ‘easy to fit’ 
interface, a breathing pattern swinging in favor of alveolar ventilation and not of dead 
space volume, and a lung distending pressure that seems to impact on work of 
breathing of COPD patients. 
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